Temozolomide-related idiosyncratic and other uncommon toxicities: A systematic review

Anti-Cancer Drugs

Volumn 23, Issue 10, 2012, Pages 1099-1106

  Dixit, Sanjay ^a   Baker, Louise ^a   Walmsley, Vicki ^a   Hingorani, Mohan ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

aplastic anemia; glioblastoma; idiosyncratic reactions; infection; pancytopenia; second primary neoplasm; temozolomide; toxicity; treatment induced myelodysplasia

Indexed keywords

ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; CILENGITIDE; COTRIMOXAZOLE; DEXAMETHASONE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYPERICUM PERFORATUM EXTRACT; LOMUSTINE; PREDNISOLONE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEMOZOLOMIDE; THYMOCYTE ANTIBODY; THYROXINE; VALPROIC ACID;

ADVERSE DRUG REACTION; ANTIBIOTIC THERAPY; ANTICONVULSANT THERAPY; APLASTIC ANEMIA; BLOOD TOXICITY; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; BRAIN ABSCESS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CHOLESTATIC HEPATITIS; CLINICAL OBSERVATION; CLINICAL TRIAL (TOPIC); CMV COLITIS; CMV PNEUMONITIS; CONVALESCENCE; DATA ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; GLIOBLASTOMA; GLIOMA; HEMORRHAGIC CYSTITIS; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HYPERICUM PERFORATUM; IDIOSYNCRATIC DRUG REACTION; INFECTION; JAUNDICE; LEUKEMIA; LIVER FAILURE; LIVER INJURY; LYMPHOMA; MEDLINE; MENINGITIS; META ANALYSIS; MYELODYSPLASTIC SYNDROME; PALMER PLANTER ERYTHRODYSESTHESIA; PNEUMONIA; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK FACTOR; SECOND CANCER; SEIZURE; SEPSIS; SEX DIFFERENCE; SYSTEMATIC REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 84867576204     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328356f5b0     Document Type: Review

References (86)

1. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005; 23:2372-2377.
2. Dario A, Tomei G. The safety of the temozolomide in patients with malignant glioma. Curr Drug Saf 2006; 1:205-222.
3. Payne MJ, Pratap SE, Middleton MR. Temozolomide in the treatment of solid tumours: Current results and rationale for dosing/scheduling. Crit Rev Oncol Hematol 2005; 53:241-252.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996.
5. Doyle TJ, Mikkelsen T, Croteau D, Ali HAJ, Beasse R, Rogers L, et al. Fatal hematologic toxicity with prolonged continuous administration of temozolomide (TMZ) during radiation therapy (RT) in the treatment of newlydiagnosed glioblastoma multiforme (GBM): Report of a phase II trial. J Clin Oncol 2005; 23:1.
6. Gerber DE, Grossman SA, Zeltzman M, Parisi MA, Kleinberg L. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro-oncology 2007; 9:47-52.
7. Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: A toxicity with therapeutic implications. J Clin Oncol 2004; 22:610-616.
8. Chamberlain MC, Raizer J. Extended exposure to alkylator chemotherapy: Delayed appearance of myelodysplasia. J Neurooncol 2009; 93: 229-232.
9. Villano JL, Cindy AC, Elisabet EM, Charulata R, Koen van B. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 2006; 7:436-438.
10. Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann R-D, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 2006; 24:4412-4417.
11. Singhal N, Selva-Nayagam S, Brown M. Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatmentcase study and review of literature. J Neurooncol 2007; 85:229-230.
12. Jalali R, Singh P, Menon H, Gujral S. Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with temozolomide. J Neurooncol 2007; 85:105-107.
13. Morris EB, Kasow K, Reiss U, Ellison D, Broniscer A. Bone marrow transplantation for severe aplastic anemia secondary to temozolomide. J Neurooncol 2009; 91:237-239.
14. Nagane M, Nozue K, Shimizu S, Waha A, Miyazaki H, Kurita H, et al. Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma - analysis of O6-methylguanine-DNA methyltransferase status. J Neurooncol 2009; 92:227-232.
15. Flowers A. Prolonged pancytopenia from combined myelotoxic effect of temozolomide and levetiracetam in a patient with glioblastoma multiforme. In: Joint Meeting of the Society for Neuro-Oncology (SNO) and the American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Section on Tumors. New Orleans: Neuro- Oncology; 2009. p. 625.
16. George BJ, Eichinger JB, Richard TJ. A rare case of aplastic anemia caused by temozolomide. South Med J 2009; 102:974-976.
17. Kopecky J, Priester P, Slovacek L, Petera J, Kopecky O, Macingova Z. Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide. Strahlenther Onkol 2010; 186:452-457.
18. Oh J, Kutas GJ, Davey P, Morrison M, Perry Jr. Aplastic anemia with concurrent temozolomide treatment in a patient with glioblastoma multiforme. Curr Oncol 2010; 17:124-126.
19. Comez G, Sevinc A, Sever ON, Babacan T, Sari I, Camci C. An unusual case of aplastic anemia caused by temozolomide. Case Rep Med 2010; 2010:975039.
20. Niewald M, Berdel C, Fleckenstein J, Ketter R, Ruebe C. Remarkable toxicity after radiochemotherapy for glioblastoma using temozolomide. Clini Oncol 2011; 23:S46-S47.
21. Sylvester RK, Steen P, Tate JM, Mehta M, Petrich RJ, Berg A, et al. Temozolomide-induced severe myelosuppression: Analysis of clinically associated polymorphisms in two patients. Anticancer Drugs 2011; 22:104-110.
22. Lata S, Molczyk A. Side effects of temozolomide treatment in patient with glioblastoma multiforme - case study. [Polish]. Przegl Lek 2010; 67: 445-446.
23. Soetekouw PM, Gijtenbeek JM, van der Maazen RW, Kappelle AC, van Herpen CM. Temozolomide, an oral chemotherapeutic agent with potential severe toxicity. [Dutch]. Ned Tijdschr Geneeskund 2007; 151:253-257.
24. Neyns B, Hoorens A, Stupp R. Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. Acta Neurol Belg 2008; 108:131-134.
25. Orzechowski HDTM, Kauffmann W, Herbst H, Bronder E, Garbe E. Severe cholestatic hepatitis after first cycle of temozolomide radiochemotherapy in a grlioblastoma patient [abstract]. Br J Clin Pharmacol 2009; 68:1-62.
26. Goldbecker A, Tryc AB, Raab P,Worthmann H, Herrmann J,Weissenborn K. Hepatic encephalopathy after treatment with temozolomide. J Neurooncol 2010; 103:163-166.
27. Dixit S, Hingorani M, Afzal P, Campbell AP. Temozolomide induced liver injury. Acta Neurol Belg 2011; 111:249-251.
28. Guilleminault L, CarréP, Diot P. Hypersensitivity pneumonitis associated with temozolomide. Eur Respir J 2009; 34:526.
29. Maldonado F, Limper AH, Lim KG, Aubry M-C. Temozolomide-associated organizing pneumonitis. Mayo Clin Proc 2007; 82:771-773.
30. Koschel D, Handzhiev S, Leucht V, Holotiuk O, Fisseler-Eckhoff A, Hoffken G. Hypersensitivity pneumonitis associated with the use of temozolomide. Eur Respir J 2009; 33:931-934.
31. Sarma N. Stevens-Johnson syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy. Am J Clin Dermatol 2009; 10:264-267.
32. Pothiawala S, Hsu MY, Yang C, Kesari S, Ibrahimi OA. Urticarial hypersensitivity reaction caused by temozolomide. J Drugs Dermatol 2010; 9:1142-1144.
33. Pick AM, Neff WJ, Nystrom KK. Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma. Pharmacotherapy 2008; 28:406-409.
34. Chheda MG, Drappatz J, Greenberger NJ, Kesari S, Weiss SE, Gigas DC, et al. Hepatitis B reactivation during glioblastoma treatment with temozolomide: A cautionary note. Neurology 2007; 68:955-956.
35. Grewal J, Dellinger CA, Yung WK. Fatal reactivation of hepatitis B with temozolomide. N Engl J Med 2007; 356:1591-1592.
36. Fujimoto Y, Hashimoto N, Kinoshita M, Miyazaki Y, Tanaka S, Yakushijin T, et al. Hepatitis B virus reactivation associated with temozolomide for malignant glioma: A case report and recommendation for prophylaxis. Int J Clin Oncol 2011;1-4.
37. Meije Y, Lizasoain M, Garcia-Reyne A, Martinez P, Rodriguez V, Lopez- Medrano F, et al. Emergence of cytomegalovirus disease in patients receiving temozolomide: Report of two cases and literature review. Clin Infect Dis 2010; 50:e73-e76.
38. De Jesus A, Grossman S, Paun O. Cytomegalovirus associated colonic pseudotumor: A consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomide. J Neurooncol 2009; 94:445-448.
39. Schwarzberg AB, Stover EH, Sengupta T, Michelini A, Vincitore M, Baden LR, et al. Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. Cancer Invest 2007; 25: 249-255.
40. Yaman E, Coskun U, Ozturk B, Buyukberber S, Kaya AO, Coskun O, et al. Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma. J Clin Neurosc 2009; 16:591-592.
41. Douzinas EE, Flevari K, Andrianakis I, Betrosian AP. Oral atovaquone for the treatment of severe Pneumocystis jirovecii pneumonia in a patient with glucose-6-phosphate dehydrogenase deficiency. Scand J Infect Dis 2010; 42:76-78.
42. Ganiere V, Christen G, Bally F, Guillou L, Pica A, de Ribaupierre S, et al. Listeria brain abscess, pneumocystis pneumonia and Kaposi's sarcoma after temozolomide. Nat Clin Pract Oncol 2006; 3:339-343, quiz following 343.
43. Grisdale K, Ritterhouse M, Hunter K, Williams M, Groves M. Tonsillar pseudotumor: Complications of chronically-administered temozolomide. J Neurooncol 2010; 100:475-479.
44. De Paiva TF Jr. de Barros e Silva MJ, Rinck JA Jr, Fanelli MF, Gimenes DL. Tuberculosis in a patient on temozolomide: A case report. J Neurooncol 2009; 92:33-35.
45. Georgescu G, Isola IM, Youssef S, Adachi J, Rolston K. Disseminated salmonellosis in a patient treated with temozolomide. J Infect 2008; 57:414-415.
46. Redelman-Sidi G, Grommes C, Papanicolaou G. Kitten-transmitted Bordetella bronchiseptica infection in a patient receiving temozolomide for glioblastoma. J Neurooncol 2011; 102:335-339.
47. Aregawi D, Lopez D, Wick M, Scheld W, Schiff D. Disseminated strongyloidiasis complicating glioblastoma therapy: A case report. J Neurooncol 2009; 94:439-443.
48. Choi JD, Powers CJ, Vredenburgh JJ, Friedman AH, Sampson JH. Cryptococcal meningitis in patients with glioma: A report of two cases. J Neurooncol 2008; 89:51-53.
49. Kanat O, Baskan B, Kurt E, Evrensel T. Successful treatment of palmar- plantar erythrodysesthesia possibly due to temozolomide with dexamethasone. J Postgrad Med 2007; 53:146-146.
50. Schreiber S, Prox-Vagedes V, Elolf E, Brueggemann I, Gademann G, Galazky I, et al. Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: A case report. BMC Cancer 2010; 10:520.
51. Islam R, Isaacson BJ, Zickerman PM, Ratanawong C, Tipping SJ. Hemorrhagic cystitis as an unexpected adverse reaction to temozolomide: Case report. Am J Clin Oncol 2002; 25:513-514.
52. Su YW, Chang MC, Chiang MF, Hsieh RK. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neurooncol 2005; 71:315-318.
53. Noronha V, Berliner N, Ballen KK, Lacy J, Kracher J, Baehring J, et al. Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature. Neuro-oncology 2006; 8:280-283.
54. Dufour C, Da Costa L, Auger N, Jullien M, Bhangoo R, Grill J. Treatmentrelated myelodysplastic syndrome after temozolomide use in a child: First report. J Pediatr Hematol Oncol 2008; 30:857-859.
55. Kushner BH, Laquaglia MP, Kramer K, Modak S, Cheung NK. Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: Possible leukemogenic role of temozolomide. Pediatric Blood Cancer 2008; 51:552-554.
56. Kim SJ, Park TS, Lee ST, Song J, Suh B, Kim SH, et al. Case report: Therapyrelated myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme. Ann Clin Lab Sci 2009; 39:392-398.
57. Natelson EA, Pyatt D. Temozolomide-induced myelodysplasia. Adv Hematol 2010; 2010:760402.
58. Momota H, Nariata Y, Miyakita Y, Hosono A, Makimoto A, Shibui S. Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. Pediatric blood Cancer 2010; 55:577-579.
59. Shaikh A, Masood N. Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: A case report. J Med Case Rep 2010; 4:274.
60. De Vita S, De Matteis S, Laurenti L, Chiusolo P, Reddiconto G, Fiorini A, et al. Secondary Ph + acute lymphoblastic leukemia after temozolomide. Ann Hematol 2005; 84:760-762.
61. Ogura M, Todo T, Tanaka M, Nannya Y, Ichikawa M, Nakamura F, et al. Temozolomide may induce therapy-related acute lymphoblastic leukaemia. Br J Haematol 2011; 154:663-665.
62. Neyns B, Cordera S, Joosens E, Nader P. Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide. Clin Oncol 2008; 26:4518-4519.
63. Binello E, Germano IM. Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: Treatment-related or dual-pathology? J Neurooncol 2009; 94:145-148.
64. Young NS. Acquired aplastic anemia. Ann Intern Med 2002; 136:534-546.
65. Montane E, Ibanez L, Vidal X, Ballarin E, Puig R, Garcia N, et al. Epidemiology of aplastic anemia: A prospective multicenter study. Haematologica 2008; 93:518-523.
66. Young NS, Kaufman DW. The epidemiology of acquired aplastic anemia. Haematologica 2008; 93:489-492.
67. Maluf E, Hamerschlak N, Cavalcanti AB, Junior AA, Eluf-Neto J, Falcao RP, et al. Incidence and risk factors of aplastic anemia in Latin American countries: The LATIN case-control study. Haematologica 2009; 94:1220-1226.
68. Villano J, Letarte N, Yu J, Abdur S, Bressler L. Hematologic adverse events associated with temozolomide. Cancer Chemother Pharmacol 2011;1-7.
69. Armstrong TS, Cao Y, Scheurer ME, Vera-Bolanos E, Manning R, Okcu MF, et al. Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors. Neuro-oncol 2009; 11:825-832.
70. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997; 23:35-61.
71. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000; 6:2585-2597.
72. Armstrong T, Gilbert M. Patient profiling for treatment toxicity: Potential use of clinical and genomic factors. Curr Oncol Rep 2011; 13:37-41.
73. Sabharwal A, Waters R, Danson S, Clamp A, Lorigan P, Thatcher N, et al. Predicting the myelotoxicity of chemotherapy: The use of pretreatment O6- methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells. Melanoma Res 2011; 21:502-508.
74. Iyer L, Das S, Janisch L,Wen M, Ramirez J, Karrison T, et al. UGT1A1[ast]28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2:43-47.
75. Hansen PB, Lauritzen AM. Aplastic anemia successfully treated with rituximab. Am J Hematol 2005; 80:292-294.
76. Ceci G, Bella M, Melissari M, Gabrielli M, Bocchi P, Cocconi G. Fatal hepatic vascular toxicity of DTIC. Is it really a rare event? Cancer 1988; 61:1988-1991.
77. Neyns B, Tosoni A, Hwu WJ, Reardon DA. Dose-dense temozolomide regimens: Antitumor activity, toxicity, and immunomodulatory effects. Cancer 2010; 116:2868-2877.
78. Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 2011; 17:5473-5480.
79. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi M, Jaeckle KA, et al. RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM) [abstract]. J Clin Oncol 2011; 29.
80. Barnard D, Woods W. Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer - an update. Leuk Lymphoma 2005; 46:651-663.
81. Greene MH, Boice JD Jr., Strike TA. Carmustine as a cause of acute nonlymphocytic leukemia. N Engl J Med 1985; 313:579.
82. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 2003; 102:43-52.
83. Pagano L, Pulsoni A, Tosti ME, Annino L, Mele A, Camera A, et al. Acute lymphoblastic leukaemia occurring as second malignancy: Report of the GIMEMA archive of adult acute leukaemia. Br J Haematol 1999; 106:1037-1040.
84. Shivakumar R, Tan W, Wilding GE, Wang ES, Wetzler M. Biologic features and treatment outcome of secondary acute lymphoblastic leukemia - a review of 101 cases. Ann Oncol 2008; 19:1634-1638.
85. Weiss B. Possible leukemogenic potential of temozolomide. Pediatric Blood Cancer 2009; 52:553.
86. Geiger H, Schleimer D, Nattamai KJ, Dannenmann SR, Davies SM, Weiss BD. Mutagenic potential of temozolomide in bone marrow cells in vivo. Blood 2006; 107:3010-3301.